Elite Pharmaceuticals Files 8-K
Ticker: ELTP · Form: 8-K · Filed: May 20, 2024 · CIK: 1053369
| Field | Detail |
|---|---|
| Company | Elite Pharmaceuticals INC /NV/ (ELTP) |
| Form Type | 8-K |
| Filed Date | May 20, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, filing
TL;DR
Elite Pharma filed an 8-K on 5/20. Details TBD.
AI Summary
Elite Pharmaceuticals, Inc. filed an 8-K on May 20, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or details about the nature of the disclosure or exhibits.
Why It Matters
This filing indicates Elite Pharmaceuticals is providing updated information or disclosures to the SEC, which could be material to investors.
Risk Assessment
Risk Level: low — The filing is a standard procedural disclosure without immediate negative or positive financial implications detailed within the provided text.
Key Players & Entities
- ELITE PHARMACEUTICALS, INC. (company) — Registrant
- 0001493152-24-020707 (filing_id) — Accession Number
- May 20, 2024 (date) — Date of Report
- 165 Ludlow Avenue, Northvale, New Jersey 07647 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is May 20, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 165 Ludlow Avenue, Northvale, New Jersey 07647.
What is the registrant's telephone number?
The registrant's telephone number, including area code, is (201) 750-2646.
What is the SIC code for Elite Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for Elite Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 536 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-05-20 16:30:31
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ELTP OTCQB Item 7.01. R
Filing Documents
- form8-k.htm (8-K) — 35KB
- ex99-1.htm (EX-99.1) — 7KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001493152-24-020707.txt ( ) — 213KB
- eltp-20240520.xsd (EX-101.SCH) — 3KB
- eltp-20240520_lab.xml (EX-101.LAB) — 33KB
- eltp-20240520_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 May 20, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 165 Ludlow Avenue , Northvale , New Jersey 07647 (Address of principal executive offices) (201) 750-2646 (Registrant's telephone number, including area code) (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ELTP OTCQB Item 7.01. Regulation FD Disclosure On May 20, 2024, in a press release, Elite Pharmaceuticals, Inc., or Elite, reported that it received approval from the US Food and Drug Administration (FDA) on May 16, 2024 for a generic version of Methotrexate Sodium ("Methotrexate") 2.5 mg tablets. Methotrexate belongs to a class of drugs known as antimetabolites and will be sold under the Elite Laboratories, Inc. label. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 7.01 and contained in the press release furnished as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and is not incorporated by reference into any of Elite's filings under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated May 20, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 20, 2024 ELITE PHARMACEUTICALS, INC. By: /s/ Nasrat Hakim Nasrat Hakim, President and CEO